Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
Holding AGEN?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$2.64Last Year’s EPS
-$2.6Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -29.49%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of promising advancements in therapy development and strategic initiatives to bolster financial stability, but also highlighted ongoing financial constraints and increased net loss. While the potential of BOT/BAL is noteworthy, the financial challenges are significant.Company Guidance
During Agenus' Q3 2024 earnings call, the company provided a comprehensive update on its clinical and financial progress, focusing on the promising results of its BOT/BAL therapy. The therapy has shown unprecedented outcomes in treating microsatellite stable (MSS) colorectal cancer and other hard-to-treat cancers, a significant advancement given the 85% of colorectal cancers that typically resist immunotherapy. Financially, Agenus ended the quarter with $44.8 million in cash and has raised an additional $7.1 million. The company emphasized its strategic focus on reducing cash outflows, monetizing real estate assets valued at over $70 million, and pursuing strategic transactions to enhance resources. The call highlighted a net loss of $67 million for Q3 2024, with revenue recognition of $25 million, while operational cash use was reduced to $129.7 million for the nine months ended September 2024, compared to $183.8 million in the same period in 2023. These financial strategies and clinical advancements underscore Agenus' commitment to redefining cancer treatment and ensuring long-term growth and patient access to BOT/BAL.Promising Results for BOT/BAL
BOT/BAL is showing unprecedented results in cancers resistant to previous therapies, including MSS colorectal cancer, which accounts for more than 85% of all colorectal cancer.
Operational Cost Reductions
The company has implemented measures to significantly reduce cash outflow, lowering operational costs from $183.8 million in the first 9 months of 2023 to $129.7 million in the same period of 2024.
Strategic Asset Monetization
Agenus is in advanced discussions to monetize real estate assets valued at over $70 million, potentially providing significant resources for future growth.
Increased Revenue
Revenue for the 3 and 9 months ended September 30, 2024, was $25 million and $77 million, respectively, compared to $24 million and $7 million for the same periods in 2023.
---
AGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $3.90 | $3.10 | -20.51% |
| Aug 08, 2024 | $5.08 | $5.28 | +3.94% |
| May 07, 2024 | $12.95 | $12.01 | -7.26% |
| Mar 14, 2024 | $13.17 | $11.99 | -8.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Agenus (AGEN) report earnings?
Agenus (AGEN) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Agenus (AGEN) earnings time?
Agenus (AGEN) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AGEN EPS forecast?
AGEN EPS forecast for the fiscal quarter 2024 (Q4) is -$2.64.
---